PMC:7317273 / 24249-24651 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T152","span":{"begin":10,"end":14},"obj":"Body_part"},{"id":"T153","span":{"begin":15,"end":31},"obj":"Body_part"},{"id":"T154","span":{"begin":26,"end":31},"obj":"Body_part"},{"id":"T155","span":{"begin":196,"end":205},"obj":"Body_part"},{"id":"T156","span":{"begin":312,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A152","pred":"fma_id","subj":"T152","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A153","pred":"fma_id","subj":"T153","obj":"http://purl.org/sig/ont/fma/fma66768"},{"id":"A154","pred":"fma_id","subj":"T154","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A155","pred":"fma_id","subj":"T155","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A156","pred":"fma_id","subj":"T156","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T48","span":{"begin":10,"end":14},"obj":"Body_part"},{"id":"T49","span":{"begin":312,"end":316},"obj":"Body_part"}],"attributes":[{"id":"A48","pred":"uberon_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A49","pred":"uberon_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T109","span":{"begin":114,"end":121},"obj":"Disease"},{"id":"T110","span":{"begin":262,"end":270},"obj":"Disease"}],"attributes":[{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T261","span":{"begin":10,"end":31},"obj":"http://purl.obolibrary.org/obo/CL_0000082"},{"id":"T262","span":{"begin":133,"end":134},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T263","span":{"begin":146,"end":147},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T264","span":{"begin":242,"end":243},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T265","span":{"begin":312,"end":316},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T266","span":{"begin":312,"end":316},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T94","span":{"begin":210,"end":213},"obj":"Chemical"}],"attributes":[{"id":"A94","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_16412"},{"id":"A95","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_52603"},{"id":"A96","pred":"chebi_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/CHEBI_89981"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PubTator","denotations":[{"id":"346","span":{"begin":122,"end":130},"obj":"Species"},{"id":"347","span":{"begin":262,"end":272},"obj":"Species"},{"id":"348","span":{"begin":210,"end":213},"obj":"Chemical"},{"id":"349","span":{"begin":114,"end":121},"obj":"Disease"}],"attributes":[{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"Tax:9606"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"Tax:2697049"},{"id":"A348","pred":"tao:has_database_id","subj":"348","obj":"MESH:D008070"},{"id":"A349","pred":"tao:has_database_id","subj":"349","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T30","span":{"begin":389,"end":401},"obj":"http://purl.obolibrary.org/obo/GO_0001525"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":215,"end":222},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0012418"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T406","span":{"begin":10,"end":14},"obj":"CL:0000082;UBERON:0002048"},{"id":"T407","span":{"begin":15,"end":25},"obj":"UBERON:0000115;CL:0000066"},{"id":"T408","span":{"begin":26,"end":31},"obj":"CL:0000066"},{"id":"T409","span":{"begin":67,"end":71},"obj":"DG_47"},{"id":"T410","span":{"begin":114,"end":121},"obj":"SP_7"},{"id":"T411","span":{"begin":210,"end":213},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T412","span":{"begin":252,"end":256},"obj":"DG_47"},{"id":"T413","span":{"begin":262,"end":272},"obj":"SP_7"},{"id":"T414","span":{"begin":285,"end":289},"obj":"DG_47"},{"id":"T415","span":{"begin":312,"end":316},"obj":"UBERON:0002048"},{"id":"T416","span":{"begin":352,"end":356},"obj":"DG_47"},{"id":"T417","span":{"begin":389,"end":401},"obj":"GO:0001525"},{"id":"T1052","span":{"begin":114,"end":121},"obj":"SP_7"}],"text":"infecting lung epithelial cells, and priming approaches to improve MSCs therapeutic efficacy for the treatment of COVID19 patients. (a) Represent a few priming approaches (priming by inflammatory cytokines and LPS, hypoxia pre-conditioning, (b) Primed MSCs, (c) SARS-CoV-2 and ‘Primed MSCs’ post-infusion in the lung, (d) Therapeutic effect exerted by MSCs (immunosuppression, reparative, angiogenesis,"}